Skip to content
New Era Korea Daily한국어로 보기

Health ministry convenes fourth pharmaceutical innovation council to spur new drug development

The health ministry and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association brought industry, experts and government together to discuss how to speed domestically developed drugs toward global markets.

By New Era Daily AIAI-writtenPublished
Illustration: Health ministry convenes fourth pharmaceutical innovation council to spur new drug development
Public health and medical care — Illustration: New Era Korea Daily · AI-generated

The health ministry said Wednesday it convened the fourth meeting of a public-private council on pharmaceutical innovation, bringing industry, experts and government together in Seoul to discuss ways to speed the development of domestically produced drugs.

The council, chaired jointly by the ministry's second vice minister and the head of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, was launched on Sept. 2 with 21 members drawn from related government bodies, industry groups, public institutions and academia.

At the meeting, participants reviewed the state of domestic development of novel biologics, improved new drugs and natural-product medicines. Forty-five new drugs have been developed and approved in Korea in the 27 years since the country's first, the anticancer treatment Sunpla, was cleared in 1999. Korea's share of new drug candidate substances stands at 6 percent, the world's third-highest level after the United States and China. Improved new drugs, a category introduced in 2008, have also produced 172 approved products, which the ministry credited with helping manage chronic diseases at home. Participants noted, however, that Korean pharmaceutical companies still struggle at the capital-intensive stages of global phase 3 clinical trials, licensing and production, and global marketing, and discussed how to better link the infrastructure that supports drug development, after concerns that candidate substances often fail to reach commercialization.

"Korea's new drug sector has grown in both quantity and quality, with its share of candidate substances now the world's third-largest, but it is also true that global phase 3 clinical trials and global marketing led by the world's major pharmaceutical companies remain insufficient," said Chung Kyung-sil, head of the ministry's health and medical policy office. "We will work to help Korean pharmaceutical companies develop and commercialize domestically developed drugs and enter global markets effectively."

Noh Yeon-hong, chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, said new drug and improved new drug development is a key field for Korean companies seeking to become global pharmaceutical giants. He said the industry itself would strengthen research and development investment and global marketing while the association works closely with the government to support development and commercialization.

Jeon Bok-hwan, a division head at the Korea Drug Development Fund, presented on the current status and outlook for domestically developed drugs, including strategies used by major global pharmaceutical companies such as using artificial intelligence to accelerate development. Shin Hae-gon, a managing director at Hanmi Pharmaceutical, shared the company's experience and the factors behind its success in taking improved new drugs and novel drugs overseas.

Building on a working-level meeting held on Nov. 4, the council also discussed ways to manage drug sales representatives more effectively, alongside measures to help generic-drug-focused companies scale up, specialize and become exporters. The health ministry said it plans to use the discussion and suggestions from the meeting in drawing up measures to promote domestic new drug development.

What this article is based on

Every fact in this article can be checked against the primary documents below.

  1. Government보건복지부 정부 보도자료· Ministry of Health and Welfare· accessed Nov. 19, 2026
  2. Government협의체 성격·구성· mohw.go.kr· accessed Nov. 19, 2026
  3. Government발언 — 국내 신약 분야 현주소와 정부 역할· mohw.go.kr· accessed Nov. 19, 2026

© New Era Korea Daily. All rights reserved.